Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the firm's stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the transaction, the chief executive officer now owns 541,905 shares of the company's stock, valued at approximately $222,181.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Metacrine Stock Performance

NASDAQ MTCR opened at $0.48 on Friday. The stock has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $0.45. The firm has a market capitalization of $20.44 million, a P/E ratio of -0.47 and a beta of -0.92. Metacrine, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $0.68. The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.15 and a current ratio of 12.15.

Get Metacrine alerts:

Metacrine (NASDAQ:MTCR – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts forecast that Metacrine, Inc. will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On Metacrine

A number of institutional investors have recently modified their holdings of MTCR. State Street Corp raised its stake in shares of Metacrine by 482.8% during the 2nd quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after buying an additional 59,800 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Metacrine by 112.5% during the 3rd quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after acquiring an additional 72,306 shares during the period. Jane Street Group LLC acquired a new stake in shares of Metacrine during the 3rd quarter valued at about $84,000. Bank of New York Mellon Corp acquired a new stake in shares of Metacrine during the 1st quarter valued at about $126,000. Finally, Bank of America Corp DE grew its position in shares of Metacrine by 10.5% during the 1st quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares during the period. Hedge funds and other institutional investors own 34.28% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research note on Wednesday, November 16th.

About Metacrine

(Get Rating)

Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.

Featured Articles

• Get a free copy of the StockNews.com research report on Metacrine (MTCR)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.